SHARE
COPY LINK

HEALTH

‘We have enough tests’: Switzerland calls on Swiss to get tested

Swiss health officials have urged anyone experiencing symptoms to get tested. Switzerland currently tests less per positive case than most European countries.

'We have enough tests': Switzerland calls on Swiss to get tested
A coronavirus testing sign in the UK. Photo: BEN STANSALL / AFP

Despite strong test capacity, the Swiss populace appears reluctant to get tested. 

Switzerland has one of the lowest test positivity rates in Europe – meaning that fewer people are tested for every positive case. 

After lagging behind the majority of Europe in testing, Switzerland has unveiled a new campaign to encourage members of the public to get tested. 

READ: Why does Switzerland carry out so few coronavirus tests?

Entitled ‘Have symptoms: Get tested’ the campaign encourages anyone experiencing “fever, cough, sore throat, shortness of breath, chest pain, loss of smell and / or taste” to get tested immediately. 

 

 

The Federal Office of Public Health (FOPH) is concerned that too few people have been getting tested for the virus and hopes to boost testing rates. 

The Swiss GP and Child Medicine Association believes that Swiss people either fail to take their symptoms seriously or don’t think they need to take a test. 

“One possible explanation for this development is that, due to the currently slightly decreasing number of cases, the need for tests, even with only mild symptoms of the disease, is not sufficiently recognised by the population,” the Association wrote

 

‘We have enough tests’

In launching the campaign, FOPH spokesperson Virginie Masserey said people should not be concerned about a lack of tests – or that they would be forced to pay. 

“There is enough test capacity, so all people with symptoms should be tested,” she said. 

“The tests are free if the criteria is met.”

The FOPH has an online quiz to be completed to see if a test is necessary. 

The test can be completed here in less than 60 seconds and is available in four languages including English, German, Italian and French.

‘Insufficient testing’

Despite the sophistication of its healthcare system and its comparative wealth, Switzerland is still not carrying out enough coronavirus testing. 

According to new figures put together by Our World in Data and published in Switzerland’s Neue Zürcher Zeitung, only four countries – Poland, Bulgaria, Croatia and Romania have tested less than Switzerland over the past seven days. 

The ‘tests per case’ is another way of explaining ‘test positivity’, which refers to how many tests need to be carried out in order to identify one positive coronavirus case. 

According to the NZZ, the data shows that testing in Switzerland is ‘insufficient’, adding that the results are ‘surprising’ and that the data indicates the virus is spreading ‘uncontrollably’. 

This is surprising, because the number of tests in Switzerland is insufficient in relation to the number of infections,” the NZZ writes.  

“This is indicated by the proportion of positive tests. According to the World Health Organisation (WHO), this should be less than 5 percent. In Switzerland it is currently still at 22.8 percent and thus at a very high level. 

“This development is alarming, as very high positivity rates indicate that the virus is spreading uncontrollably. 

“The number of tests carried out in Switzerland is therefore not sufficient to be able to understand the infection process.”

More information about testing can be found here

 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.
For members

HEALTH

Which medications in Switzerland are set to become more expensive?

The cost of medications in Switzerland is already quite a bit higher than elsewhere in Europe. And now certain drugs will become even pricier.

Which medications in Switzerland are set to become more expensive?

Swiss consumers pay significantly more for their medicines than those in neighbouring European countries. 

This is what emerges from various data published over the years.

“In Switzerland, we pay far too much for medicines compared to abroad,” Matthias Müller, a spokesperson for SantéSuisse, an umbrella group for Swiss health insurance providers, told Swiss media in 2023. 

Even the price of many generic medicines is twice as high in Switzerland as in nine EU countries.

For instance, generics are on average 48 percent cheaper in Belgium, Denmark, Germany, Finland, France, Great Britain, the Netherlands, Austria and Sweden than in Switzerland, according to a price comparison.

And prices for a number of commonly-used drugs will rise even further in the near future.

Why is that?

The Federal Office of Public Health (FOPH) is adapting a new model for calculating the distribution margin. 

A distribution margin is the difference between the distributor’s cost of acquiring goods and the price at which those goods are sold.

From July 1st, 2024, inexpensive medicines whose factory price is less than, or equal to, 15 francs will become more expensive.

This change will affect more than half of medications currently being sold in Switzerland.

As a result of this move, “additional costs of several hundred million will be passed on to patients,” according to Intergenrika, which represents generic drug manufacturers in Switzerland. 

In a nutshell, consumers will pay slightly lower prices for medicines that were previously more expensive, but will also end up paying more  for those that are currently cheaper – like generics.

Which meds will become more expensive?

Pain medications are among those set to become pricier.

One of them is ibuprofen, a popular anti-inflammatory.

While a box of 20 400-mg tablets today costs 5.92 francs, its price will practically double to 11 francs from July 1st.

Though its manufacturing cost will remain the same as today – 1.58 francs – the distribution margin will increase from 4.19 to 9.09 francs.

The same goes for another often-used pain medication, Ponstan.

Ten 500-mg tablets will cost 11.21 francs instead of 6.19 currently.

The manufacturer will continue to charge 1.82 francs for the drug, but the distribution margin will increase from 4.22 to 9.11 francs.

And even generic drugs, which are cheaper – and often by much – will get pricier, at consumers’ expense.

Will some drugs be cheaper?

Yes, some will become slightly less expensive.

One example is the anticoagulant Rivaroxaban whose price will drop from 281 to 267 francs.

READ ALSO: Why you will pay more for certain drugs in Switzerland 2024?

SHOW COMMENTS